TFFD rVSV SARS2 GP vaccine - TFF Pharmaceuticals/United States Army Medical Research Institute of Infectious Diseases
Alternative Names: Recombinant vesicular stomatitis virus severe acute respiratory syndrome coronavirus-2 glycoprotein vaccine; TFFD-rVSV-SARS2-GP; TFFD-rVSV-SARS2-GP vaccineLatest Information Update: 21 Mar 2022
At a glance
- Originator TFF Pharmaceuticals
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 17 Mar 2022 TFF Pharmaceuticals establishes CRADA with the US Army Medical Research Institute of Infectious Diseases for the development of recombinant vesicular stomatitis virus severe acute respiratory syndrome coronavirus-2 glycoprotein vaccine against SARS-CoV-2 infections
- 17 Mar 2022 Early research in COVID-2019 infections (Prevention) in USA (Intranasal)